CLOSEOUT LETTER
Nikkiso Co, Ltd. MARCS-CMS 613109 —
- Product:
- Medical Devices
- Recipient:
-
Recipient NameKoichi Kato
-
Recipient TitleRepresentative Director, President & Chief Executive Officer
- Nikkiso Co, Ltd.
20-3, Ebisu 4-Chome, Shibuya-ku
Tokyo
150-6022
Japan
- Issuing Office:
- Center for Devices and Radiological Health
United States
United States
Dear Koichi Kato:
The Food and Drug Administration has completed an evaluation of Nikkiso’s corrective actions in response to our Warning Letter (CMS #613109; dated May 7th, 2021). Based on our evaluation, it appears that you have addressed the violation(s) contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.
This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
Sincerely,
/S/
Michael J. Hoffmann
Director
OHT3: Office of GastroRenal, ObGyn,
General Hospital, and Urology Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health
Food and Drug Administration